Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 5Prostatic Neoplasms 1Lymphoma, B-Cell 1Advanced Non-small Cell Lung Cancer 1

Interventions

Docetaxel 4pembrolizumab 2Carboplatin 2tislelizumab 1nazartinib 1lenvatinib 1cemiplimab 1aflutinib 1abivertinib 1Rosuvastatin Calcium 1Platinum Compounds 1Pemetrexed 1Nivolumab 1Midazolam 1Gefitinib 1Food 1Esomeprazole 1Dabigatran 1Cisplatin 1Axitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Advanced Non-small Cell Lung Cancer × abivertinib × Clear all
NCT03856697 2019-02-27

Abivertinib Maleate Versus Geifitinib in Patients With Advanced Non-small Cell Lung Cancer With Sensitive EGFR Mutation

Hangzhou ACEA Pharmaceutical Research Co., Ltd.

Phase 3 Unknown
406 enrolled
Thoracic

Advanced Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡